Company Description
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.
Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
The company’s products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas.
The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | Dec 18, 2020 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 246 |
| CEO | Kevin Knopp |
Contact Details
Address: 645 Summer Street Boston, Massachusetts 02210 United States | |
| Phone | 857 254 1500 |
| Website | 908devices.com |
Stock Details
| Ticker Symbol | MASS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001555279 |
| CUSIP Number | 65443P102 |
| ISIN Number | US65443P1021 |
| Employer ID | 45-4524096 |
| SIC Code | 3829 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin J. Knopp Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Christopher David Brown Ph.D. | Co-Founder and Board Advisor |
| Joseph H. Griffith IV | Chief Financial Officer and Treasurer |
| Michael S. Turner Esq., J.D. | Chief Legal and Administrative Officer and Secretary |
| Barbara Russo | Vice President of Marketing and Corporate Communications |
| Don Osmer | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | SCHEDULE 13G/A | Filing |
| Apr 7, 2025 | SCHEDULE 13G | Filing |
| Mar 7, 2025 | 8-K/A | [Amend] Current report |
| Mar 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |